UCB S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UCBJF research report →
About the company
UCB S. A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders.
- CEO
- Jean-Christophe Tellier
- IPO
- 2008
- Employees
- 9,052
- HQ
- Brussels, BE
Price Chart
- Market Cap
- $58.55B
- P/E
- 31.65
- P/S
- 6.38
- P/B
- 4.54
- EV/EBITDA
- 27.55
- Div Yield
- 0.56%
- Gross Margin
- 74.29%
- Op Margin
- 25.32%
- Net Margin
- 20.13%
- ROE
- 15.16%
- ROIC
- 12.13%
- Revenue
- $7.74B · 25.78%
- Net Income
- $1.56B · 46.24%
- EPS
- $8.20 · 46.17%
- Op Income
- $1.17B
- FCF YoY
- 104.49%
- 52W High
- $345.39
- 52W Low
- $194.76
- 50D MA
- $291.53
- 200D MA
- $292.55
- Beta
- 0.20
- Avg Volume
- 522
Get TickerSpark's AI analysis on UCBJF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our UCBJF coverage
Recent articles, reports, and earnings notes.
No research on UCBJF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UCBJF report →Similar companies
Peers in the same neighborhood.